Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2015 May 1.

Published in final edited form as: Stat Biopharm Res. 2014 May 27;6(2):185–197. doi: 10.1080/19466315.2014.906365

Table 5.

MTD Recommendation and in-trial allocation for scenario C

	Group 1						Group 2
	d₁	d₂	d₃	d₄	d₅	d₆	d₁	d₂	d₃	d₄	d₅	d₆
R_i(d_k)	.02	.19	.31	.45	.51	.63	.03	.05	.11	.21	.39	.50
	Ratio of N₁/N₂ = 20/12
Prop (MTD)
Scheme I	1	31	55	13	0	0	1	31	55	13	0	0
Scheme II	9	45	37	9	0	0	1	6	35	41	15	0
Scheme III	9	48	36	7	0	0	0	11	55	32	2	0
Scheme IV	20	68	12	0	0	0	0	2	51	41	6	0
Prop (pts)
Scheme I	8	25	45	19	3	0	8	27	44	19	3	0
Scheme II	17	30	35	15	3	0	13	7	32	33	16	0
Scheme III	16	34	36	12	2	0	4	12	38	32	12	0
Scheme IV	29	50	19	2	0		3	4	36	42	13	3
	Ratio of N₁/N₂ = 16/16
Prop (MTD)
Scheme I	1	21	56	22	0	0	1	21	56	22	0	0
Scheme II	9	43	38	8	0	0	0	5	32	46	16	0
Scheme III	11	48	33	8	0	0	1	9	58	32	1	0
Scheme IV	25	63	11	0	0	0	0	2	55	40	3	0
Prop (pts)
Scheme I	7	19	45	24	5	0	7	20	45	24	5	0
Scheme II	19	28	35	15	3	0	10	6	30	37	16	0
Scheme III	17	32	35	13	2	0	5	11	40	33	10	0
Scheme IV	35	46	18	1	0	0	3	4	41	40	10	2